estradiol and progesterone
BIJUVA (estradiol and progesterone) is estrogen receptor agonists [moa]. First approved in 2018.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
BIJUVA is an oral capsule combining estradiol and progesterone, approved in 2018 for hormone replacement therapy in menopausal women. It works as an estrogen receptor agonist to alleviate vasomotor symptoms and other menopausal manifestations. The fixed-dose combination offers a convenient single-capsule regimen for systemic hormone replacement.
Product is at peak commercial maturity with modest Medicare utilization; brand team likely focused on market penetration rather than growth acceleration.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
BIJUVA roles focus on defending market position and maximizing existing patient share in a mature, stable market with no active clinical expansion. Professionals on this team benefit from deep expertise in hormone replacement therapy and women's health, but with limited upside growth potential.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo